Abstract Purpose: To synthesize a series of novel 3-ethyl-2-substituted amino-quinazolin-4(3H)-ones and evaluate them for their analgesic and anti-inflammatory activities.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of acute and chronic inflammation, pain and fever. Most NSAIDs act via inhibition of cyclooxygenase, thus preventing prostaglandin biosynthesis. However, this mechanism of action is also responsible for their main undesirable effects, gastrointestinal (GI) ulceration and, less frequently, nephrotoxicity. Increase in hospitalization and deaths due to GI-related disorders parallels increased use of NSAIDs.
Therefore, the discovery of new safer antiinflammatory drugs represents a challenging goal for such a research area [1] [2] [3] [4] .
In the course of our going medicinal chemistry research program it was found that quinazolines and condensed quinazolines exhibit potent central nervous system (CNS) activities including analgesic, anti-inflammatory [5] and anticonvulsant behavior [6] . Quinazolin-4(3H)-ones with 2,3-substitution are reported to possess significant analgesic, anti-inflammatory [7, 8] and anticonvulsant activities [9] . Earlier, we have documented some lead 2-phenyl-3-substituted quinazolines (Figure 1, I ) [10] , 2-methyl-3-substituted quinazolines (Figure 1 , II) [11] , 2-methylthio-3-substituted quinazaolines ( Figure 1 , III) [12] , and 2,3-disubstituted quinazolines [13] that exhibited good analgesic and anti-inflammatory properties.
The present work is an extension of our ongoing efforts towards the development and identification of new molecules for analgesic and anti-inflammatory activities. The objective of the present study was to synthesize a series of 3-ethyl-2-substitutedamino-quinazolin-4(3H)-ones and evaluate them for their analgesic and antiinflammatory activities. 
EXPERIMENTAL Chemistry
Melting points (mp) were taken in open capillaries on a Thomas Hoover melting point apparatus and are uncorrected. IR spectra of the synthesized compounds were recorded by FT-IR (Shimadzu, Japan) using KBr pellet ( max in cm -1 ). The NMR spectra of the synthesized compounds were recorded in deuterated chloroform (CDCl 3 ) (unless specified) with tetramethyl silane (TMS) as internal reference (chemical shift in , ppm) using Varian 300 MHz and Bruker 500 MHz (Washington, USA) spectrometers. The mass spectra of the compounds were obtained on Jeol GC mate instrument (Masspec, Japan). Elemental analyses were performed in Perkin-Elmer 2400 CHN elemental analyzer (Waltham, USA). The progress of the reaction was monitored on readymade silica gel plates (Merck) using chloroform : methanol (9:1) as a solvent system. Iodine was used as a developing agent.
3-Ethyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (4)
A solution of ethylamine (1.31 g, 0.02 mol) in dimethyl sulfoxide (10 mL) was stirred vigorously. To this was added carbon disulphide (1.6 mL) and aqueous sodium hydroxide (1.2 mL of 20 M solution) dropwise during 30 min with stirring. Dimethyl sulphate (2.5 g, 0.02 mol) was then added gradually, keeping the reaction mixture in freezing mixture with stirring which was continued for further 2 h. The reaction mixture was then poured into ice-water and the solid obtained was filtered, washed with water, dried and recrystallized from 95 % ethanol.
Methyl anthranilate (3) (1.5 g; 0.01 mol) and the above prepared N-(ethyl) methyl dithiocarbamic acid (0.01 mol) were dissolved in ethanol (20 mL). To this anhydrous potassium carbonate (100 mg) was added and refluxed for 23 h. The reaction mixture was cooled in ice and the solid separated was filtered and purified by dissolving in 10 % alcoholic sodium hydroxide solution (2N) and re-precipitating by treatment with 20 % dilute hydrocholoric acid. The solid obtained was filtered, washed with water, and dried. It was recrystallized from 95 % ethanol to afford (4).
3-Ethyl-2-methylsulfanyl-3H-quinazolin-4-one (5)
The compound, 3-ethyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (4) (2.05 g, 0.01 mol), was dissolved in 40 mL of 2 % ethanol-sodium hydroxide solution (2N). To this, dimethyl sulfate (5.0 mL, 0.01 mol) was added dropwise for 15 min with stirring. The stirring was continued for 1 h, the reaction mixture was then poured into ice water. The solid obtained was filtered, washed with water, dried and recrystallized from 95 % ethanol.
3-Ethyl-2-hydrazino--3H-quinazolin-4-one (6)
The compound, 3-ethyl-2-methylsulfanyl-3H-quinazolin-4-one (5) (2.19 g, 0.01 mol), was dissolved in ethanol (95 %, 25 mL). To this, hydrazine hydrate (99 %) (0.5 mL, 0.1 mol) and anhydrous potassium carbonate (100 mg) was added and refluxed for 28 h at inert atmosphere. The reaction mixture was cooled and poured into ice-water. The solid obtained was filtered, washed with water, dried and recrystallized from chloroform : toluene (25:75) mixture.
3-Ethyl-2-(cyclohexylidene-hydrazino)-3H-quinazolin-4-one (AS1)
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) (800 mg, 0.004 mol) and cyclohexanone (0.004 mol) in glacial acetic acid (0.25 mL) was refluxed for 30 h. The reaction mixture was poured into ice water and filter. The solid filter cake was recrystallized from ethanol.
3-Ethyl-2-(N-(4-nitro-benzylidene-hydrazino))-3H-quinazolin-4-one (AS2)
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) (800 mg, 0.004 mol) and 4-nitro benzalhedyde (605 mg, 0.004 mol) in glacial 
NaOH
Scheme 1: Synthesis of 3-ethyl-2-substitutedamino-3H-quinazolin-4-ones acetic acid (0.25 mL) was refluxed for 33 h. The reaction mixture was poured into ice water and filter. The solid filter cake was recrystallized from ethanol.
3-Ethyl-2-(N-(4-methoxy-benzylidenehydrazino))-3H-quinazolin-4-one (AS3)
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) (800 mg, 0.004 mol) and 4-methoxy benzalhedyde (545 mg, 0.004 mol) in glacial acetic acid (0.25 mL) was refluxed for 32 h. The reaction mixture was poured into ice water and filter. The solid filter cake was recrystallized from ethanol.
3-Ethyl-2-(N-(4-methyl-benzylidenehydrazino)-3H-quinazolin-4-one (AS4)
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) (800 mg, 0.004 mol) and 4-methyl benzalhedyde (480 mg, 0.004 mol) in glacial acetic acid (0.25 mL) was refluxed for 30 h. The reaction mixture was poured into ice water and filter. The solid filter cake was recrystallized from ethanol.
3-Ethyl-2-(N-phenyl-benzylidene-hydrazino)-3H-quinazolin-4-one (AS5)
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) (800 mg, 0.004 mol) and diphenyl ketone (730 mg, 0.004 mol) in glacial acetic acid (0.25 mL) was refluxed for 35 h. The reaction mixture was poured into ice water and filter. The solid filter cake was recrystallized from ethanol.
Animal studies
The synthesized compounds were evaluated for analgesic and anti-inflammatory activities. The test compounds and the standard drugs were administered in the form of a suspension (1 % AA (%) = {(T2 -T1)/(10 -T1)}100 ……… (1) where T 1 is the reaction time (s) before treatment, and T 2 the reaction time (s) after treatment.
Anti-inflammatory activity
Anti-inflammatory activity was evaluated by carrageenan-induced paw oedema test in Wistar Albino rats [17] . Diclofenac sodium (5, 10 and 20 mg/kg) was administered as a standard drug for comparison. The test compounds were administered orally at three dose levels of 5, 10 and 20 mg/kg. Paw volume was measured using mercury displacement technique with the aid of a plethysmograph immediately before and 30 min, 1, 2 and 3 h after carrageenan injection. Inhibition (I, %) of paw oedema was calculated as in Eq 2.
where x is mean paw volume of the rats before administration of carrageenan and test compounds or reference compound (test group), a is the mean paw volume of rats after the administration of carrageenan in the test group (drug-treated), b is the mean paw volume of rats after the administration of carrageenan in the control group, y is the mean paw volume of rats before administration of carrageenan in the control group. 
Statistical analysis

RESULTS
The key intermediate 3-ethyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 4 (Scheme 1) was prepared by reacting ethyl amine (1) H NMR spectra of 4 showed multiplet around δ 1.0-2.0 and 7.10-7.50 for ethyl (5H) protons and aromatic (4H) protons respectively; and a singlet at δ 10.55 indicating the presence of NH. Data from elemental analysis were in conformity with the assigned structure. Further, the molecular ion recorded in the mass spectra is also in agreement with the molecular weight of the compound.
The IR spectra of compound 5 showed disappearance of NH and C=S stretching signals of cyclic thiourea. It showed a peak for carbonyl (C=O) stretching at 1680 cm -1 . The 1 H NMR spectra of compound 5 showed singlets due to SCH 3 , at δ 2.70, multiplet around 7.20-7.60 for aromatic (4H) protons, respectively. Data from the elemental analyses and molecular ion recorded in the mass spectra further confirmed the assigned structure.
Nucleophilic displacement of methylthio group of 5 with hydrazine hydrate was carried out using ethanol as solvent to afford 3-ethyl-2-hydrazino-3H-quinazolin-4-one 6. The formation of 6 was confirmed by 1 H NMR spectra which showed singlets at  4.56 and 10.31 due to NH 2 and NH, respectively, a multiplet at δ 1-1.5 and 7. 15-7.30 for ethyl (5H) protons and aromatic (4H) protons respectively. The NH and NH 2 signals at 3330, 3205 cm -1 are appeared in the IR spectra. It also showed a peak for carbonyl (C=O) at 1670 cm -1 . Data from the elemental analyses are in conformity with the assigned structure. Further, the molecular ion recorded in the mass spectra is also in agreement with the molecular weight of the compound.
The compounds, 3-ethyl-2-substituted amino-3H-quinazolin-4-ones AS1 -AS5 were obtained by the condensation of amino group of 3-ethyl-2-hydrazino-3H-quinazolin-4-one (6) with a variety of aldehydes and ketones. Formation of product is indicated by the disappearance of peak due to NH 2 of the starting material in IR and 1 H NMR spectrum of all the compounds AS1 -AS5. The IR 1 H NMR spectra of these compounds showed the presence of peaks due to (N=CR 1 R 2 ) carbonyl (C=O), NH and aryl groups. The mass spectra of the the compounds show molecular ion peaks corresponding to their molecular formula. In the mass spectra of compounds AS1 -AS5, a common peak at m/z 144 corresponding to quinazolin-4-one moiety appeared. Elemental (C, H, N) analysis satisfactorily confirmed rhe elemental composition and purity of the synthesized compounds.
3-Ethyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (4)
Yield = 85 %, mp 290-291°C; IR (KBr) cm -2-(N-(4-nitro-benzylidene-hydrazino) The results of analgesic testing indicate that the test compounds exhibited moderate analgesic activity at 30 min of reaction time and an increase in activity at 1 h which reached a peak level at 2 h. Decline in activity was observed at 3 h (Table 1) .
3-Ethyl-2-hydrazino--3H-quinazolin-4-one (6)
Yield = 80
3-Ethyl
3-Ethyl-2-(N-(4-methoxy-benzylidenehydrazino))-3H-quinazolin-4-one (AS3)
Yield
3-Ethyl-2-(N-(4-methyl-benzylidenehydrazino)-3H-quinazolin-4-one (AS4)
Anti-inflammatory activity data (Table 2) indicate that all the test compounds protected rats from carrageenan-induced inflammation moderately at 30 min of reaction time with increased activity at 1 h that reached a peak level at 2 h. Decline in activity was observed at 3 h. 
DISCUSSION
All the synthesized compounds were confirmed by spectral data (IR, NMR and mass spectra). Elemental (C, H, N) analysis satisfactorily confirmed elemental composition and purity of the synthesized compounds.
Compound AS1 with 1-cyclohexylidene substituent showed good analgesic activity. Replacement of an alkyl chain at the C-2 position with aryl group (compound AS3, AS4, AS5) leads to decrease in analgesic activity. Placement of aryl group with electron withdrawing substituent (compounds AS5) leads to further decrease of analgesic activity. Compound 3-ethyl-2-(cyclohexylidene-hydrazino)-3H-quinazolin-4-one (AS1) emerged as the most active analgesic agent and it is moderately more potent than the reference standard, diclofenac sodium. The compound, 3-ethyl-2-(cyclohexylidene-hydrazino)-3H-quinazolin-4-one (AS1), emerged the most active antiinflammatory agent. Replacement of an alkyl chain at the C-2 position with aryl group (compound AS3, AS4, AS5) leads to decrease in anti-inflammatory activity. Placement of aryl group with electron withdrawing substituent (compound AS5) led to further decrease of antiinflammatory activity.
CONCLUSION
The synthesized compounds exhibited promising analgesic and anti-inflammatory activities. Among them, compound 3-ethyl-2-(cyclohexylidene-hydrazino)-3H-quinazolin-4-one (AS1) is the most active compound of the series and is as potent as the reference standard (diclofenac sodium). Hence, this compound is a potential lead molecule for a clinically useful novel class of analgesic and anti-inflammatory agents.
